CN Patent

CN114502564A — Egfr抑制剂、组合物及其制备方法

Assigned to Betta Pharmaceuticals Co Ltd · Expires 2022-05-13 · 4y expired

What this patent protects

一种式I化合物，使用这些化合物作为EGFR抑制剂的方法，以及包含这些化合物的药物组合物。该化合物可用于治疗、预防或改善诸如癌症或感染的疾病或病症。

USPTO Abstract

一种式I化合物，使用这些化合物作为EGFR抑制剂的方法，以及包含这些化合物的药物组合物。该化合物可用于治疗、预防或改善诸如癌症或感染的疾病或病症。

Drugs covered by this patent

Patent Metadata

Patent number
CN114502564A
Jurisdiction
CN
Classification
—
Expires
2022-05-13
Drug substance claim
No
Drug product claim
No
Assignee
Betta Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.